Cohort Study on Refractive Errors in Preschool Children (PREC)
Refractive error is a common visual disorder encompassing myopia, hyperopia, astigmatism and other subtypes. Refractive error in preschool children refers to refractive abnormalities occurring during the preschool period (0-6 years old). Studies conducted across diverse regions and populations report that the prevalence of refractive error among preschool children ranges approximately from 10% to 30%, with this proportion showing a gradual upward trend in recent years. Existing evidence suggests that preschool refractive status is correlated with multiple ocular and systemic diseases. Furthermore, the preschool years represent a highly sensitive window for children's visual development; uncorrected refractive errors at this stage can disrupt visual maturation and induce permanent visual impairment. Accordingly, identifying the full spectrum of comorbidities associated with preschool refractive error, alongside implementing early diagnosis and intervention, is clinically critical.
Nevertheless, substantial challenges persist in the clinical management of preschool refractive errors: the complete comorbidity spectrum remains undefined, its natural history has not been fully elucidated, and high-quality evidence-based guidelines for refractive correction and visual rehabilitation are lacking. Establishing a prospective cohort of preschool children with refractive errors is therefore of great significance for clarifying disease progression and risk factors, generating evidence for standardized refractive interventions and visual rehabilitation protocols, and ultimately preventing visual impairment and improving quality of life in this vulnerable pediatric population.
Our research team has previously completed preliminary investigations characterizing myopia in preschoolers. Building on this foundational work, we aim to construct a dedicated cohort of preschool children with refractive errors to delineate the natural history, progression risks and comorbidity profiles of preschool refractive error, and explore effective refractive correction and visual rehabilitation approaches for affected young children.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xiao Yang
- Numéro de téléphone: 13760766303
- E-mail: yangx_zoc@163.com
Lieux d'étude
-
-
Guanzhou
-
Guangdong, Guanzhou, Chine, 510060
- Zhongshan Ophthalmic Center Sun Yat-Sen University
-
Contact:
- Xiao Yang
- Numéro de téléphone: 13760766303
- E-mail: yangx_zoc@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Onset of refractive error occurs during preschool age (0-6 years old) supported by retrievable medical records;
- Spherical equivalent power ≤ -0.50 D or ≥ +3.00 D in any meridian;
- Legal guardians agree to participate and sign written informed consent.
Exclusion Criteria:
Children unable to cooperate with examinations and follow-up visits.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Refractive error
Refractive error in preschool children
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ocular Biometry Parameters
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
A set of objective ocular structural measurements mainly including axial length (AL), alongside corneal curvature, anterior chamber depth, lens thickness and vitreous chamber depth.
Axial length, the core indicator in this study, refers to the linear distance from the anterior corneal surface to the retinal pigment epithelium, which is closely associated with the onset and progression of refractive errors in preschool children.
All biometric indices will be measured using standardized ophthalmic biometry equipment at each follow-up visit to dynamically observe the developmental rules of ocular dimensions and their correlation with refractive status.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
BCVA
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Visual Acuity Examination
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
Contrast Sensitivity
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
CSF
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
SER
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Spherical Equivalent Refraction，Comprehensive index reflecting overall ocular refractive status, integrating myopia, hyperopia and astigmatism.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
WES (Whole Exome Sequencing)
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Genetic sequencing results of all protein-coding regions to detect gene variants related to refractive disorders.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
OCT
Délai: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
OCT Imaging Findings
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2023KYPJ340-2
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .